Mustafa Oğuz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mustafa Oğuz has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Faysal Şaylık
Van Training and Research Hospital, Department of Cardiology, Health Sciences University, 65300 Van, Turkey
4 shared publications - Mert Babaoğlu
Sultan II. Abdulhamid Training and Research Hospital Department of Cardiology, University of Health Sciences, Istanbul, Turkey
4 shared publications Murat Demirci
Department of Cardiology, Marmara University Medical School, Istanbul, Turkey
4 shared publications- Murat Demirci
Marmara University
4 shared publications Tayyar Akbulut
SBU Van Training and Research Hospital
4 shared publications- Tufan Çınar
School of Medicine, University of Maryland, Baltimore, MD 21201, USA
4 shared publications
Latest Publications
- Open Access
- 15 August 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (4) , 756-763
Prognostic significance of serum LA index, and HALP score in patients with pulmonary embolism
Aims: Pulmonary embolism (PE) remains a major cause of morbidity and mortality, and early identification of high-risk patients is essential for guiding clinical management. Nutritional and inflammatory biomarkers such as serum LA index (lymphocyte count×serum albumin level), and composite indices including the HALP (hemoglobin×albumin×lymphocyte/platelet) score have recently gained attention for their prognostic value in acute cardiovascular and thromboembolic conditions. However, their clinical utility in predicting acute and late mortality in PE has not been fully clarified. Methods: This retrospective study included 693 adult patients diagnosed with acute PE by computed tomography pulmonary angiography between 2016 and 2024. Demographic, clinical, laboratory, and echocardiographic parameters were collected. The prognostic performances of LA index, HALP score, and NLR were evaluated for predicting in-hospital and five year all-cause mortality using ROC analysis. Logistic regression was performed to identify independent predictors of mortality. Results: Of the 693 patients, 40 died during the index hospitalization and 653 were discharged alive. Among the discharged patients, 282 died during the 5-year follow-up period, while 371 remained alive at 5 years. Non-survivors were older and had significantly higher rates of hypertension, diabetes mellitus, chronic obstructive pulmonary disease, arrhythmia, and malignancy (all p
- 15 August 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (4) , 756-763
Open AccessPrognostic significance of serum LA index, and HALP score in patients with pulmonary embolism
Aims: Pulmonary embolism (PE) remains a major cause of morbidity and mortality, and early identification of high-risk patients is essential for guiding clinical management. Nutritional and inflammatory biomarkers such as serum LA index (lymphocyte count×serum albumin level), and composite indices including the HALP (hemoglobin×albumin×lymphocyte/platelet) score have recently gained attention for their prognostic value in acute cardiovascular and thromboembolic conditions. However, their clinical utility in predicting acute and late mortality in PE has not been fully clarified. Methods: This retrospective study included 693 adult patients diagnosed with acute PE by computed tomography pulmonary angiography between 2016 and 2024. Demographic, clinical, laboratory, and echocardiographic parameters were collected. The prognostic performances of LA index, HALP score, and NLR were evaluated for predicting in-hospital and five year all-cause mortality using ROC analysis. Logistic regression was performed to identify independent predictors of mortality. Results: Of the 693 patients, 40 died during the index hospitalization and 653 were discharged alive. Among the discharged patients, 282 died during the 5-year follow-up period, while 371 remained alive at 5 years. Non-survivors were older and had significantly higher rates of hypertension, diabetes mellitus, chronic obstructive pulmonary disease, arrhythmia, and malignancy (all p
- Open Access
- 9 March 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (3) , 125
Correction: Cicek et al. A New Risk Prediction Model for the Assessment of Myocardial Injury in Elderly Patients Undergoing Non-Elective Surgery. J. Cardiovasc. Dev. Dis. 2025, 12, 6
- 9 March 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (3) , 125
Open AccessCorrection: Cicek et al. A New Risk Prediction Model for the Assessment of Myocardial Injury in Elderly Patients Undergoing Non-Elective Surgery. J. Cardiovasc. Dev. Dis. 2025, 12, 6
- Open Access
- 8 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (32) , e43940
The role of statins in modulating subclinical inflammatory markers in coronary slow flow phenomenon
Coronary slow flow phenomenon (CSFP) is characterized by slow coronary blood flow in the absence of significant stenosis, and its pathophysiology is associated with endothelial dysfunction, microvascular abnormalities, and inflammation. This study aimed to investigate the effects of statin therapy on subclinical inflammatory markers in CSFP patients. This retrospective cohort study included patients diagnosed with CSFP by using coronary angiography. The patients were divided into statin and control groups based on the initiation of statin therapy. Inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) were assessed at baseline and 3 months later. At baseline, NLR, PLR, SII, and SIRI levels were comparable between the 2 groups. After 3 months, these markers were significantly lower in the statin group. In the statin group, the NLR, PLR, SII, and SIRI levels significantly decreased from baseline, whereas no significant changes were observed in the control group. The reduction in inflammatory marker levels was more pronounced in patients receiving high-dose statins. Statin therapy is associated with reduced subclinical inflammation in CSFP, supporting the inflammatory basis and therapeutic value of statins.
- 8 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (32) , e43940
Open AccessThe role of statins in modulating subclinical inflammatory markers in coronary slow flow phenomenon
Coronary slow flow phenomenon (CSFP) is characterized by slow coronary blood flow in the absence of significant stenosis, and its pathophysiology is associated with endothelial dysfunction, microvascular abnormalities, and inflammation. This study aimed to investigate the effects of statin therapy on subclinical inflammatory markers in CSFP patients. This retrospective cohort study included patients diagnosed with CSFP by using coronary angiography. The patients were divided into statin and control groups based on the initiation of statin therapy. Inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) were assessed at baseline and 3 months later. At baseline, NLR, PLR, SII, and SIRI levels were comparable between the 2 groups. After 3 months, these markers were significantly lower in the statin group. In the statin group, the NLR, PLR, SII, and SIRI levels significantly decreased from baseline, whereas no significant changes were observed in the control group. The reduction in inflammatory marker levels was more pronounced in patients receiving high-dose statins. Statin therapy is associated with reduced subclinical inflammation in CSFP, supporting the inflammatory basis and therapeutic value of statins.
- 29 May 2025
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 53 (8) , 1838-1845
Cardiac Dysfunction and 5‐Year Mortality in Patients With Systemic Sclerosis and Interstitial Lung Disease: A Speckle‐Tracking Echocardiography Study
Background/Aims: Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by fibrosis, vascular abnormalities, and immune system activation, often leading to significant cardiac involvement and high mortality. Interstitial lung disease (ILD) is a common complication in SSc, potentially exacerbating cardiac dysfunction. This study aimed to evaluate cardiac function using speckle‐tracking echocardiography (STE) and determine the impact of ILD on 5‐year mortality in SSc patients.Methods: In this prospective cohort study, 68 SSc patients were divided into two groups based on the presence of ILD, assessed by thoracic computed tomography (CT): ILD group (n = 32) and non‐ILD group (n = 36). Both conventional echocardiography and STE were performed to assess cardiac function, with left ventricular global longitudinal strain (LV GLS) and right ventricular global longitudinal strain (RV GLS) as primary measures. Five‐year mortality data were collected and analyzed.Results: The ILD group exhibited significantly lower LV GLS (−15.62% ± 2.74%) and RV GLS (−16.46% ± 4.38%) compared to the non‐ILD group (−18.01% ± 2.73%, p = 0.001 and −20.22% ± 4.30%, p = 0.001, respectively). Atrial strain parameters, including both left and right atrial reservoir and contractile strain, were significantly impaired in the ILD group. Five‐year all‐cause mortality was significantly higher in the ILD group (46.87%) compared to the non‐ILD group (19.44%, p = 0.016). Multivariate logistic regression identified age (OR = 1.120, 95% CI: 1.022–1.226, p = 0.015) and RV GLS (OR = 0.686, 95% CI: 0.550–0.856, p = 0.001) as independent predictors of mortality. RV GLS predicted 5‐year mortality with a sensitivity of 86.4% and a specificity of 80.4% at a cut‐off value of −17.3%.Conclusion: SSc patients with ILD exhibit significant cardiac dysfunction and higher 5‐year mortality compared to those without ILD.
- 29 May 2025
- Published by Wiley in Journal of Clinical Ultrasound
- Vol. 53 (8) , 1838-1845
Cardiac Dysfunction and 5‐Year Mortality in Patients With Systemic Sclerosis and Interstitial Lung Disease: A Speckle‐Tracking Echocardiography Study
Background/Aims: Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by fibrosis, vascular abnormalities, and immune system activation, often leading to significant cardiac involvement and high mortality. Interstitial lung disease (ILD) is a common complication in SSc, potentially exacerbating cardiac dysfunction. This study aimed to evaluate cardiac function using speckle‐tracking echocardiography (STE) and determine the impact of ILD on 5‐year mortality in SSc patients.Methods: In this prospective cohort study, 68 SSc patients were divided into two groups based on the presence of ILD, assessed by thoracic computed tomography (CT): ILD group (n = 32) and non‐ILD group (n = 36). Both conventional echocardiography and STE were performed to assess cardiac function, with left ventricular global longitudinal strain (LV GLS) and right ventricular global longitudinal strain (RV GLS) as primary measures. Five‐year mortality data were collected and analyzed.Results: The ILD group exhibited significantly lower LV GLS (−15.62% ± 2.74%) and RV GLS (−16.46% ± 4.38%) compared to the non‐ILD group (−18.01% ± 2.73%, p = 0.001 and −20.22% ± 4.30%, p = 0.001, respectively). Atrial strain parameters, including both left and right atrial reservoir and contractile strain, were significantly impaired in the ILD group. Five‐year all‐cause mortality was significantly higher in the ILD group (46.87%) compared to the non‐ILD group (19.44%, p = 0.016). Multivariate logistic regression identified age (OR = 1.120, 95% CI: 1.022–1.226, p = 0.015) and RV GLS (OR = 0.686, 95% CI: 0.550–0.856, p = 0.001) as independent predictors of mortality. RV GLS predicted 5‐year mortality with a sensitivity of 86.4% and a specificity of 80.4% at a cut‐off value of −17.3%.Conclusion: SSc patients with ILD exhibit significant cardiac dysfunction and higher 5‐year mortality compared to those without ILD.
- 24 March 2025
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 19 (8) , 295-304
Coronary artery ectasia prediction: the role of the Intermountain Risk Score in identifying patients at risk
This study evaluates the association between the Intermountain Risk Score (IMRS) and coronary artery ectasia (CAE) to determine its predictive value. A retrospective study was conducted at a tertiary hospital from January 2019 to January 2024. A total of 446 patients (226 with CAE, 220 controls) were included. Clinical, laboratory, and angiographic data were analyzed. IMRS was calculated based on routine demographic and laboratory parameters. Statistical analyses included logistic regression and receiver operating characteristic (ROC) curve analysis. Patients with CAE had significantly higher IMRS scores (p = 0.011) and were more likely to fall into high-risk IMRS categories (p = 0.002). Smoking (HR: 3.744, p = 0.045), mean corpuscular volume (HR: 1.105, p = 0.019), and IMRS color category (HR: 5.255, p = 0.016) were independent predictors. ROC analysis showed an AUC of 0.617 for IMRS score and 0.627 for IMRS color category. IMRS is a significant predictor of CAE and may serve as a practical risk stratification tool. Higher-risk patients could benefit from closer monitoring and targeted interventions. Further validation in prospective studies is needed.
- 24 March 2025
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 19 (8) , 295-304
Coronary artery ectasia prediction: the role of the Intermountain Risk Score in identifying patients at risk
This study evaluates the association between the Intermountain Risk Score (IMRS) and coronary artery ectasia (CAE) to determine its predictive value. A retrospective study was conducted at a tertiary hospital from January 2019 to January 2024. A total of 446 patients (226 with CAE, 220 controls) were included. Clinical, laboratory, and angiographic data were analyzed. IMRS was calculated based on routine demographic and laboratory parameters. Statistical analyses included logistic regression and receiver operating characteristic (ROC) curve analysis. Patients with CAE had significantly higher IMRS scores (p = 0.011) and were more likely to fall into high-risk IMRS categories (p = 0.002). Smoking (HR: 3.744, p = 0.045), mean corpuscular volume (HR: 1.105, p = 0.019), and IMRS color category (HR: 5.255, p = 0.016) were independent predictors. ROC analysis showed an AUC of 0.617 for IMRS score and 0.627 for IMRS color category. IMRS is a significant predictor of CAE and may serve as a practical risk stratification tool. Higher-risk patients could benefit from closer monitoring and targeted interventions. Further validation in prospective studies is needed.
- 21 March 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 70 (2) , 274
Regional and Global Aortic Pulse Wave Velocity in Patients with Abdominal Aortic Aneurysm
- 21 March 2025
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 70 (2) , 274
Regional and Global Aortic Pulse Wave Velocity in Patients with Abdominal Aortic Aneurysm
- 19 February 2025
- Published by Elsevier in Heart & Lung
- Vol. 71, 106
Letter to the Editor: Efficacy and safety of iloprost in the treatment of pulmonary arterial hypertension: A systematic review and meta-analysis
- 19 February 2025
- Published by Elsevier in Heart & Lung
- Vol. 71, 106
Letter to the Editor: Efficacy and safety of iloprost in the treatment of pulmonary arterial hypertension: A systematic review and meta-analysis
- Open Access
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Advances in Interventional Cardiology
- Vol. 21 (2) , 289-290
Comment on “Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis”
- 1 January 2025
- Published by Termedia Sp. z.o.o. in Advances in Interventional Cardiology
- Vol. 21 (2) , 289-290
Open AccessComment on “Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis”